Back
For best output, select "Paper Size" as "A4" and "Margin" as "0" or "None".
To save or print to PDF, please select Print Destination > Save as PDF, enable Background Graphics under "More Settings", then click "Save".
During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center.
Preparing your E-Poster
Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.
E-Poster Submission Deadline
Please prepare and upload your E-Poster no later than March 14, 2026 11.59PM CET. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.
Please follow the instructions below to input your abstract title.
Abstract titles should be brief and reflect the content of the abstract.
HELLP-spectrum disorders are severe hypertensive complications characterized by endothelial injury, hepatic dysfunction, and systemic inflammation. When complicated by acute kidney injury (AKI) and heart failure, outcomes remain poor despite delivery and supportive care. Hemoperfusion (HP) using HA-330-II, which adsorbs bilirubin, bile acids, ammonia, myoglobin, and pro-inflammatory cytokines, offers adjunct detoxification but is under-reported in obstetric AKI.
A 44-year-old G4P4 woman presented with progressive dyspnea and bilateral edema after treatment elsewhere for pre-eclampsia with severe features. On admission: BP 170/100 mmHg, RR 32 cpm, SpO₂ 96% (intubated). She underwent emergency cesarean section for worsening respiratory distress due to pulmonary congestion and was admitted to PACU.Exam: bibasal crackles, grade 3 edema.Initial laboratories: WBC 21.2 × 10⁹/L, Hgb 113 g/L, Plt 283 × 10⁹/L; creatinine 135.3 µmol/L, BUN 14.8 mmol/L (BCR 8.4), eGFR 43 mL/min/1.73 m²; Na 132.6 mmol/L, K 5.23 mmol/L, Mg 3.14 mmol/L, iCa 1.10 mmol/L, P 1.78 mmol/L; AST 323 U/L, ALT 236 U/L, LDH 890 U/L; total bilirubin 9.4 mg/dL (direct 2.7, indirect 6.7); D-dimer 1.732 µg/mL FEU; Procalcitonin 18 ng/mL. UA: +1 protein, 10–20 WBC/hpf; UPCR 0.29. ABG: pH 7.19, HCO₃ 10.2 mmol/L, pCO₂ 20 mmHg (primary metabolic acidosis). CXR: cardiomegaly with congestion. Echocardiography: LVEF 31.5% (acute heart failure/peripartum cardiomyopathy).Impressions: partial HELLP, intrinsic AKI (ischemic ATN), acute pulmonary congestion.Given oliguria, volume overload, and rising hepatic markers, she underwent three sequential sessions of HD+HP using HA-330-II (each: 3 h HD → 3 h HP, BFR 150 mL/min, UF 3 L; bicarbonate dialysate; low-flux membrane).
After the first HD+HP, urine output rose to 1.25 L/24 h and pulmonary congestion regressed; oxygenation normalized and she was extubated after the second session (transitioned to BiPAP). Serial improvements followed: LDH 890 → 362 U/L, AST 323 → 24 U/L, ALT 236 → 29 U/L, total bilirubin 9.4 → 1.5 mg/dL, creatinine 135.3 → 98.6 µmol/L, BUN 14.8 → 10.8 mmol/L, eGFR 43 → >60 mL/min/1.73 m², Procalcitonin 18 → 0.31 ng/mL, and normalization of electrolytes (K 5.23 → 3.68 mmol/L; Mg 3.14 → 0.90 mmol/L). Follow-up CXR showed near-complete clearance of congestion.
Sequential HD+HP with HA-330-II was associated with rapid improvement in renal, hepatic, and cardiopulmonary parameters in partial HELLP–associated AKI with heart failure. By adsorbing bilirubin/bile acids and inflammatory mediators alongside dialytic solute and fluid control, HA-330-II likely reduced metabolic and cytokine burden, serving as a bridge to organ recovery. These findings support further evaluation of standardized timing and session protocols for HP in HELLP-spectrum multiorgan dysfunction, particularly in resource-limited obstetric nephrology settings.
